Literature DB >> 30593641

Isolation of HCV Neutralizing Antibodies by Yeast Display.

Zhen-Yong Keck1, Yong Wang1, Patrick Lau1, Steven K H Foung2.   

Abstract

Yeast surface display (YSD) enables efficient screening and selection of single chain variable fragments (scFvs) of heavy (VH) and light (VL) chains that bind to target antigen with different affinities. Assembly of a scFv library from cDNA usually involves adding different primers and linkers (Gly4/Ser)3 through multiple rounds of PCR amplification and purification. We describe here a simplified scFv assembly method by creating a modified YSD vector with a built-in linker that reduces the time of assembly and decreases accumulated base exchanges due to PCR errors. In addition, we describe a bias screening strategy toward maximizing novel antibodies of interest by a combination of memory B cell selection and depletion by binding to mutant antigens that do not bind to previously identified monoclonal antibodies.

Entities:  

Keywords:  Hepatitis C virus; Human monoclonal antibody isolation; Mutant antigen selection; Virus neutralization; Yeast surface display

Mesh:

Substances:

Year:  2019        PMID: 30593641      PMCID: PMC6375674          DOI: 10.1007/978-1-4939-8976-8_27

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  14 in total

Review 1.  Construction and screening of antigen targeted immune yeast surface display antibody libraries.

Authors:  Keith D Miller; Noah B Pefaur; Cheryl L Baird
Journal:  Curr Protoc Cytom       Date:  2008-07

2.  Combining Phage and Yeast Cell Surface Antibody Display to Identify Novel Cell Type-Selective Internalizing Human Monoclonal Antibodies.

Authors:  Scott Bidlingmaier; Yang Su; Bin Liu
Journal:  Methods Mol Biol       Date:  2015

3.  Yeast surface display for screening combinatorial polypeptide libraries.

Authors:  E T Boder; K D Wittrup
Journal:  Nat Biotechnol       Date:  1997-06       Impact factor: 54.908

Review 4.  Phage and Yeast Display.

Authors:  Jared Sheehan; Wayne A Marasco
Journal:  Microbiol Spectr       Date:  2015-02

5.  Stabilizing antibody secretion of human Epstein Barr virus-activated B-lymphocytes with hybridoma formation by electrofusion.

Authors:  S Perkins; S K Foung
Journal:  Methods Mol Biol       Date:  1995

6.  Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes.

Authors:  K G Hadlock; R E Lanford; S Perkins; J Rowe; Q Yang; S Levy; P Pileri; S Abrignani; S K Foung
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

7.  Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library.

Authors:  Michael J Feldhaus; Robert W Siegel; Lee K Opresko; James R Coleman; Jane M Weaver Feldhaus; Yik A Yeung; Jennifer R Cochran; Peter Heinzelman; David Colby; Jeffrey Swers; Christilyn Graff; H Steven Wiley; K Dane Wittrup
Journal:  Nat Biotechnol       Date:  2003-01-21       Impact factor: 54.908

Review 8.  Yeast display of antibody fragments: a discovery and characterization platform.

Authors:  Michael J Feldhaus; Robert W Siegel
Journal:  J Immunol Methods       Date:  2004-07       Impact factor: 2.303

9.  Yeast surface display for antibody isolation: library construction, library screening, and affinity maturation.

Authors:  James A Van Deventer; Karl Dane Wittrup
Journal:  Methods Mol Biol       Date:  2014

10.  Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen.

Authors:  Kenneth Smith; Lori Garman; Jens Wrammert; Nai-Ying Zheng; J Donald Capra; Rafi Ahmed; Patrick C Wilson
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

View more
  4 in total

1.  An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein.

Authors:  Abdolkarim Sheikhi; Mohammad Hojjat-Farsangi
Journal:  Hum Vaccin Immunother       Date:  2020-07-14       Impact factor: 3.452

Review 2.  An overview of some potential immunotherapeutic options against COVID-19.

Authors:  Maryam Bayat; Yahya Asemani; Mohammad Reza Mohammadi; Mahsa Sanaei; Mozhdeh Namvarpour; Reyhaneh Eftekhari
Journal:  Int Immunopharmacol       Date:  2021-02-26       Impact factor: 5.714

Review 3.  Emergence of novel coronavirus and progress toward treatment and vaccine.

Authors:  Muhammad Muzamil Khan; Amna Noor; Asadullah Madni; Mudassir Shafiq
Journal:  Rev Med Virol       Date:  2020-06-04       Impact factor: 11.043

Review 4.  SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic.

Authors:  Ali A Rabaan; Shamsah H Al-Ahmed; Ranjit Sah; Ruchi Tiwari; Mohd Iqbal Yatoo; Shailesh Kumar Patel; Mamta Pathak; Yashpal Singh Malik; Kuldeep Dhama; Karam Pal Singh; D Katterine Bonilla-Aldana; Shafiul Haque; Dayron F Martinez-Pulgarin; Alfonso J Rodriguez-Morales; Hakan Leblebicioglu
Journal:  Ann Clin Microbiol Antimicrob       Date:  2020-09-02       Impact factor: 3.944

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.